Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Marc H. Feinberg et al.|The Lancet Neurology|2023Cited by 255
Protease-Activated Receptor (PAR) 1 and PAR4 Differentially Regulate Factor V Expression from Human PlateletsMatthew T. Duvernay, Heidi E. Hamm|Molecular Pharmacology|2013Cited by 73
Anterograde Trafficking of G Protein-Coupled Receptors: Function of the C-Terminal F(X)6LL Motif in Export from the Endoplasmic ReticulumMatthew T. Duvernay, Guangyu Wu|Molecular Pharmacology|2009Cited by 69